AbbVie Files US FDA BLA for Etentamig in Multiple Myeloma
AbbVie has submitted Biologics License Application (BLA) for Etentamig to US FDA for adults living with Relapsed/Refractory Multiple Myeloma (RRMM).
Etentamig | 03/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy